From epigenetic mechanisms to cancer therapeutics
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.
Updates from current CLL clinical trials
Targeting ROR1 and a two-drug approach to cure CLL
What are the economics of treating CLL?